How Tylenol turned into a target for Trump

It's perhaps surprising that a product so widely used would become a medicinal scapegoat.

September 25, 2025 Check out STAT+

Sponsored By

Charlie Knoblock/AP STAT+ | From an elixir for 'little hotheads' to deadly overdoses, how Tylenol became a medicinal scapegoat Tylenol's history spans kids' medicine, deadly overdoses, and corporate crises. Now Trump's autism claims put acetaminophen in a crossfire By Megan Molteni Autistic moms feel shamed and stigmatized by Trump's Tylenol warning Autistic community says Trump's Tylenol claims are spreading shame and stigma, evoking painful memories of the 'refrigerator mom' myth By O. Rose Broderick STAT+ | As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity A ribbon-cutting ceremony in Harwell, England, shows how the U.K. has plans to be a hub of mRNA activity as the U.S. cuts back mRNA research under RFK Jr. By Andrew Joseph Courtesy NYU STAT+ | Inside NYU's AI-powered plan to catch osteoporosis with repurposed CT scans NYU plans to start checking newly acquired CT scans for osteoporosis, a condition that often goes undiagnosed By Katie Palmer Opinion: A $100,000 fee for H-1B visas will devastate U.S. health care Indian-born immigrant doctors in America have been pioneers, innovators, and lifesavers whose work has made medicine stronger By Geeta Minocha STAT reporters break down Trump's announcement on Tylenol, autism and vaccines President Trump's announcement on autism gained huge attention this week. STAT's Alex Hogan spoke with colleagues who provided key context and explanations. By Alex Hogan Adobe Opinion: How President Trump's remarks about autism hurt autistic people like me Donald Trump's and RFK Jr.'s rhetoric returns us to a time when autism was seen as something ugly. That's damaging to the autistic community By David Rivera STAT+ | Uniqure and its Huntington's therapy win the week in biotech In this week's edition of "Adam's Biotech Scorecard," Adam looks at data from Uniqure and explains why investors are gravitating toward Soleno Therapeutics. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser